Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Inovio Pharmaceuticals Inc INO

Healthcare Biotechnology
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:INO)

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

PR Newswire 10 days ago

INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine

PR Newswire March 26, 2024

INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

PR Newswire March 6, 2024

Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting

PR Newswire March 6, 2024

INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024

PR Newswire February 21, 2024

INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

PR Newswire February 7, 2024

INOVIO Reports Inducement Grant Under Inducement Plan

PR Newswire February 2, 2024

INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split

PR Newswire January 23, 2024

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

PR Newswire January 22, 2024
View More News ››

Opinion & Analysis (NDAQ:INO)

Acceleration of COVID-19 Vaccine Programs Could Benefit U.S. Biotech

Streetwise Reports May 14, 2020

Inovio Pharma Awarded $9M Development Grant for Coronavirus Vaccine

Streetwise Reports January 28, 2020

Coverage Initiated on Immunotherapies Developer with 'Catalyst Rich 2020'

Streetwise Reports December 27, 2019

Immuno-oncology Firm to Co-Develop Companion Diagnostic for Cervical Dysplasia

Streetwise Reports May 27, 2019

Immunotherapeutic Agent Shows Efficacy in Rare Respiratory Disease

Streetwise Reports April 11, 2019

After Financing Close, Biotech's Subsidiary to Operate Independently

Streetwise Reports March 6, 2019
View More Opinion ››

Bullboard Posts (NDAQ:INO)

INO announced stock split 1-12

BREAKING NEWS: $INO INO announced stock split 1-122024-01-24 08:02:09 ET Inovio Pharmaceuticals Inc (INO) announced stock split at a...
whytestocks - January 24, 2024

Kevin Harrington Discusses FSD Pharma

<< View Post To Watch Video >> I believe this new product will aid society in reducing the number of alcohol-related...
JayDestura - April 13, 2023

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent

 
JayDestura - July 13, 2022

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

<< View Post To Watch Video >> FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets...
JayDestura - June 3, 2022

FSD Pharma Files Investigational New Drug Application “IND”

 
JayDestura - June 1, 2022

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

 
JayDestura - May 10, 2022
View more Bullboard ››

Full Circle Lithium Corp.

Full Circle Lithium Corp.

Situated in the epicentre of the largest EV buildout in USA history, Full Circle Lithium is a Georgia based full-service ...
View More »